CSL Shares Rally Strongly Despite Earnings Dip
As many analysts had forecast, constraints on plasma collection (especially in the US) led to a small dip in December half-year earnings for blood products colossus CSL.
Read More
Csl Limited
Over a century ago in Melbourne, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
Videos
Videos coming soon for Csl Limited.
All Csl Limited Content
News
CSL Finally Confirms $A16 Billion Vifor Deal
CSL announced late Tuesday that it has struck a deal to buy Swiss-based Vifor Pharma Ltd for $A16.4 billion, its biggest deal since listing in 1994.
Read More
CSL Confirms Vifor Talks
After weeks of speculation that CSL was looking to bid for Swiss pharma firm Vifor, the companies have today confirmed they are in talks.
Read More
Profit Briefs: CSL, AMC
With peak reporting season upon us, here are snippets from the results announced yesterday by a couple of big-name multinational companies: CSL Limited and Amcor.
Read More
COVID a Tonic For CSL, Sonic
COVID has been good news for two of Australia’s health giants - Sonic Healthcare and CSL which both revealed very strong double-digit profits on Thursday for the six months to December.
Read More
Analyst Views
CSL – Macquarie rates the stock as Outperform
The broker retains an Outperform rating and lowers the target to $312.00 from $327.25.
Read More
CSL – Morgan Stanley rates the stock as Overweight
The Overweight rating and $310 target are retained.
Read More
CSL – Morgan Stanley rates the stock as Overweight
The $302 target price and Overweight rating are maintained.
Read More
CSL – Morgans rates the stock as Add
Add rating retained. Target price eases to $327.60 from $334.70.
Read More
CSL – Morgan Stanley rates the stock as Equal-weight
Equal-weight and $280 target retained.
Read More
